GU Cancers 2021 | Gemcitabine plus doxorubicin for RMC
Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a retrospective study analyzing the use of gemcitabine plus doxorubicin (Gem+Dox) in patients with renal medullary carcinoma (RMC). RMC is characterized by loss of SMARCB1. Loss of SMARCB1 induces replication stress, subsequently making RMC cells vulnerable to nucleoside analogs. This analysis, which included data from 16 patients with RMC, most of whom has previously been treated with platinum-based chemotherapy, found that Gem+Dox achieved a partial response in 21.4% of patients and achieved stable disease in 71.4% of patients with a median progression-free survival (PFS) of 3 months. The median overall survival (OS) from Gem+Dox initiation was 9.8 months. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Pavlos Msaouel, MD, PhD, has received honoraria from Mirati Therapeutics, Exelixis, and Bristol-Myers Squibb; has received consulting fees from Axiom Healthcare Strategies; has participated in non-branded educational programs supported by Exelixis and Pfizer; and has received research funding from Takeda, Bristol-Myers Squibb, Mirati Therapeutics, Gateway for Cancer Research and the University of Texas MD Anderson Cancer Center.
